The allotment of shares in the offer was completed on Wednesday and the shares were credited to demat accounts on Thursday. The company raised Rs 895 crore through a mix of new issues and sale offer.The IPO, which was open for bidding between November 21 and 25, saw strong participation from all investor categories, resulting in a total subscription of 93.71 times. Qualified institutional buyers subscribed 213.08 times, making it one of the most sought-after QIB entries in the chemicals and ingredients segment this year.
Wealthy investors subscribed 116.72 times, while the retail book was withdrawn 15.65 times. Demand from institutional investors was also reflected in a sizeable anchor round, with Sudeep Pharma raising Rs 268.50 crore out of the 45.27 lakh shares allotted on November 20. The first half of the anchor lock-in ends on December 26.
The IPO was priced at Rs 593 per share, the top end of the Rs 563-593 band. At a GMP of around 20%, the indicative listing price is between Rs 700 and Rs 720, although actual performance will depend on broader market sentiment and recent volatility observed in midcaps and specialty chemicals.
Company overview
Sudeep Pharma produces pharmaceutical excipients, food grade minerals and specialty food ingredients. It is one of India’s largest players in its segment and supplies to more than 100 countries. The company operates six manufacturing facilities with a combined capacity of 50,000 tons, producing mineral-based ingredients for pharmaceuticals, nutraceuticals, food processing and specialty food products. The portfolio includes more than 200 products across specialty calcium, magnesium, iron, potassium, zinc and sodium ingredients, along with triturates and high-performance excipients used by global pharmaceutical majors.
The company has built strong R&D capabilities, supported by internal laboratories and pilot plants specializing in mineral salts and ingredient innovation. Its customer base is global and diversified, with long-standing relationships with leading pharmaceutical, food and nutrition brands.
On the financial front, Sudeep Pharma has reported consistent growth over the last three financial years. Revenue rose from Rs 465.38 crore in FY24 to Rs 511.33 crore in FY25, an increase of 10%, while net profit rose from Rs 133.15 crore to Rs 138.69 crore. For the June 2025 quarter, the company reported a revenue of Rs 130.08 crore and a profit of Rs 31.27 crore.
EBITDA for FY25 stood at Rs 199.28 crore, which translates into a margin of 39.70%. PAT margin was 27.63%, reflecting robust fundamentals and operational efficiencies. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.20 and reserves of Rs 668.52 crore as of FY25.
At the issue price, the company has a market capitalization of around Rs 6,698 crore. The post-issue price-to-earnings ratio comes to 53.55 times based on June 2025 annualized earnings, putting it ahead of some peers, although the company’s high-margin profile and leadership in specialty ingredients have helped maintain investor interest.
Proceeds from the fresh issue will mainly go towards capital expenditure for procurement of machinery at the company’s Nandesari Facility I, worth Rs 75.81 crore. The remainder will be used for general corporate purposes.
Also read: An overlooked FII trade explodes with flows of Rs 43,000 crore. Will 2026 belong to Jio, Airtel?
The stock’s performance in the secondary market will depend on how investors value margin stability and growth prospects within the broader specialty chemicals ecosystem.
(Disclaimer: Recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of Economic Times)
#Strong #start #Sudeep #Pharma #shares #trading #premium #IPO #price